The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice

Grassia, G., Maddaluno, M., Guglielmotti, A., Mangano, G., Biondi, G., Maffia, P. and Ialenti, A. (2009) The anti-inflammatory agent bindarit inhibits neointima formation in both rats and hyperlipidaemic mice. Cardiovascular Research, 84(3), pp. 485-493. (doi: 10.1093/cvr/cvp238) (PMID:19592568) (PMCID:PMC2777949)

[img]
Preview
Text
45983.pdf - Published Version

406kB

Abstract

Aims Bindarit is an original compound with peculiar anti-inflammatory activity due to a selective inhibition of a subfamily of inflammatory chemokines, including the monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7, and MCP-2/CCL8. In this study, we investigated the effect of bindarit on neointima formation using two animal models of arterial injury: rat carotid artery balloon angioplasty and wireinduced carotid injury in apolipoprotein E-deficient (apoE2/2) mice. Methods and results Treatment of rats with bindarit (200 mg/kg/day) significantly reduced balloon injury-induced neointima formation by 39% at day 14 without affecting re-endothelialization and reduced the number of medial and neointimal proliferating cells at day 7 by 54 and 30%, respectively. These effects were associated with a significant reduction of MCP-1 levels both in sera and in injured carotid arteries of rats treated with bindarit. In addition, in vitro data showed that bindarit (10– 300 mM) reduced rat vascular smooth muscle cell (VSMC) proliferation, migration, and invasion, processes contributing to the injury-induced neointima formation in vivo. Similar results were observed in hypercholesterolaemic apoE2/2 mice in which bindarit administration resulted in a 42% reduction of the number of proliferating cells at day 7 after carotid injury and in a 47% inhibition of neointima formation at day 28. Analysis of the cellular composition in neointimal lesions of apoE2/2 mice treated with bindarit showed that the relative content of macrophages and the number of VSMCs were reduced by 66 and 30%, respectively, compared with the control group. Conclusion This study demonstrates that bindarit is effective in reducing neointima formation in both non-hyperlipidaemic and hyperlipidaemic animal models of vascular injury by a direct effect on VSMC proliferation and migration and by reducing neointimal macrophage content. All of these data were associated with the inhibition of MCP-1 production.

Item Type:Articles
Keywords:Bindarit; Neointima hyperplasia; Monocyte chemoattractant protein-1; Macrophages; Vascular smooth muscle cells
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Maffia, Dr Pasquale and Grassia, Dr Gianluca
Authors: Grassia, G., Maddaluno, M., Guglielmotti, A., Mangano, G., Biondi, G., Maffia, P., and Ialenti, A.
Subjects:R Medicine > RB Pathology
R Medicine > RM Therapeutics. Pharmacology
College/School:College of Medical Veterinary and Life Sciences
College of Medical Veterinary and Life Sciences > Institute of Infection Immunity and Inflammation
Journal Name:Cardiovascular Research
Journal Abbr.:Cardiovasc Res
Publisher:Oxford University Press
ISSN:0008-6363
ISSN (Online):1755-3245
Published Online:10 July 2009
Copyright Holders:Copyright © 2009 Oxford University Press
First Published:First Published in Cardiovascular Research 84(3):485-493
Publisher Policy:Reproduced in accordance with the copyright policy of the publisher

University Staff: Request a correction | Enlighten Editors: Update this record